Cellceutix Corp.’s (CTIX.OB) New Autism Drug Research on Compound KM-391 Results in Significant Behavioral Changes
This morning before the opening bell, Cellceutix Corp. announced that a new animal study of its compound for autism spectrum disorder, KM-391, further demonstrated a positive impact on several measures of behavior associated with autism. As announced by the company last week, Cellceutix expedited the research through a collaborative effort with InterEd Faculty of Clinical Research (IFCR) in India and the prestigious Cochin University of Science & Technology (CUSAT). In the study, test subjects were injected with a compound to simulate autistic behaviors then injected with an oxytocin antagonist to intensify the symptoms. Test subjects were divided into four groups,…